Literature DB >> 2895889

Somatostatin receptor subtypes in the clonal anterior pituitary cell lines AtT-20 and GH3.

K Thermos1, T Reisine.   

Abstract

The functional and biochemical characteristics of somatostatin (somatotropin release-inhibiting factor) (SRIF) receptor subtypes were examined in the clonal pituitary cell lines AtT-20 and GH3. SRIF inhibits evoked calcium influx into each of these cell lines. The rank order of potencies of structural analogues of SRIF to inhibit calcium influx into GH3 versus AtT-20 cells was different. Inhibitory actions of SRIF on calcium influx desensitized in AtT-20 cells but not GH3 cells. The biochemical properties of the SRIF receptor subtypes in AtT-20 and GH3 cells were assessed by photoaffinity labeling of each receptor with the nonreducible SRIF analogue [125I]CGP 23996 and the photocrosslinking agent n-hydroxysuccinimidyl-4-azidobenzoate. The covalently labeled receptors in both cell lines had the same size, 55 +/- 5 kDa, as assessed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The covalent binding of [125I]CGP-23996 to GH3 and AtT-20 cell membranes was blocked by 1 microM SRIF, somatostatin 28, Trp8-SRIF and was GTP sensitive. Analysis of the labeled receptors in GH3 and AtT-20 cell membranes by two-dimensional polyacrylamide gel electrophoresis indicated that they were of similar charge (pI = 6-6.5) and that they comigrate when applied together. Proteolysis of the GH3 and AtT-20 cell SRIF receptors with Staphylococcus aureus V-8 and thermolysin revealed similar peptide maps. Pretreatment of AtT-20 cells with different stable SRIF analogues abolished the subsequent equilibrium or covalent labeling of the SRIF receptor with [125I]CGP-23996. Similar treatment of GH3 cells did not reduce the covalent labeling of the SRIF receptor by [125I]CGP 23996. These studies indicate that the functional characteristics of SRIF receptors in GH3 and AtT-20 cells are different. However, clear differences in the biochemical properties of these receptor subtypes were not observed. Subtle variations in the structure of the SRIF receptors may therefore be responsible for the functional differences.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2895889

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  11 in total

1.  Development of antibodies against the rat brain somatostatin receptor.

Authors:  M Theveniau; S Rens-Domiano; S F Law; G Rougon; T Reisine
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-15       Impact factor: 11.205

2.  Tissue-specific distribution of cross-linked somatostatin receptor proteins in the rat.

Authors:  C B Srikant; K K Murthy; Y C Patel
Journal:  Biochem J       Date:  1992-03-01       Impact factor: 3.857

Review 3.  Molecular pharmacology of somatostatin receptor subtypes.

Authors:  Y C Patel
Journal:  J Endocrinol Invest       Date:  1997-06       Impact factor: 4.256

4.  Somatostatin-14 and somatostatin-28 induce opposite effects on potassium currents in rat neocortical neurons.

Authors:  H L Wang; C Bogen; T Reisine; M Dichter
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

5.  Purification of a putative brain somatostatin receptor.

Authors:  H T He; K Johnson; K Thermos; T Reisine
Journal:  Proc Natl Acad Sci U S A       Date:  1989-03       Impact factor: 11.205

6.  The effect of albumin fusion structure on the production and bioactivity of the somatostatin-28 fusion protein in Pichia pastoris.

Authors:  Yuedi Ding; Jun Fan; Wenxin Li; Ying Peng; Runlin Yang; Lili Deng; Qiang Fu
Journal:  J Ind Microbiol Biotechnol       Date:  2014-04-22       Impact factor: 3.346

7.  Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study.

Authors:  E Kouroumalis; P Skordilis; K Thermos; A Vasilaki; J Moschandrea; O N Manousos
Journal:  Gut       Date:  1998-03       Impact factor: 23.059

Review 8.  Molecular pharmacology of somatostatin receptors.

Authors:  D Hoyer; H Lübbert; C Bruns
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-11       Impact factor: 3.000

9.  Effects of acute and chronic desipramine treatment on somatostatin receptors in brain.

Authors:  E G Gheorvassaki; K Thermos; G Liapakis; C Spyraki
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

10.  Pharmacological characterisation of native somatostatin receptors in AtT-20 mouse tumour corticotrophs.

Authors:  Davide Cervia; Caroline Nunn; Dominique Fehlmann; Daniel Langenegger; Edi Schuepbach; Daniel Hoyer
Journal:  Br J Pharmacol       Date:  2003-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.